Adma Biologics (ADMA) Other Non Operating Income (2018 - 2025)

Adma Biologics has reported Other Non Operating Income for 8 years, with the latest figure at $3.0 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non Operating Income fell 31.01% year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2025 stood at -$406000.0 (down 109.59% YoY), and the FY2025 full-year result was $2.8 million, down 35.51% from the prior year.
• Other Non Operating Income for Q4 2025 stood at $3.0 million, up from -$2.2 million in the prior quarter.
• The five-year high for Other Non Operating Income was $4.3 million in Q4 2024, with the low at -$6.7 million in Q1 2022.
• Historically, Other Non Operating Income has averaged -$181588.2 across 5 years, with a median of -$35000.0 in 2024.
• Annual changes were most pronounced in 2023 — Other Non Operating Income tumbled 171086.44% — and 2024, when it surged 4397.03%.
• Adma Biologics' Other Non Operating Income stood at $106772.0 in 2021, then slumped by 100.06% to -$59.0 in 2022, then plunged by 171086.44% to -$101000.0 in 2023, then surged by 4397.03% to $4.3 million in 2024, then plunged by 31.01% to $3.0 million in 2025.
• The last three Other Non Operating Income figures came in at $3.0 million (Q4 2025), -$2.2 million (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.